NCT01661881 2026-04-08
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
23 trialsNCT03623373 2026-03-30
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT04115631 2026-03-23
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06854003 2026-02-20
BRAZAN
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07206264 2025-10-03
ADAPT-MCL
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT03834688 2025-08-11
PrE0405
PrECOG, LLC.
Phase 2 Completed
NCT03872180 2025-08-06
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Emory University
Phase 2 Active not recruiting
NCT04792489 2025-04-24
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT01415752 2025-04-08
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT01437709 2025-02-28
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03311126 2024-10-24
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
University of Wisconsin, Madison
Phase 2 Terminated
NCT05868395 2024-05-29
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
Medical University of Vienna
Phase 2 Recruiting
NCT06136351 2023-11-29
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Ruijin Hospital
Phase 2 Recruiting
NCT01662050 2022-08-09
FIL-RBAC500
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT01412879 2021-10-29
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT04913103 2021-06-04
CLSGMCLPOLA
Czech Lymphoma Study Group
Phase 2 Not yet recruiting
NCT01737177 2018-03-09
R2-B
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT01110135 2017-05-24
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
Phase 2 Completed
NCT00740415 2016-03-16
ManteauRiBVD
French Innovative Leukemia Organisation
Phase 2 Completed
NCT00891839 2014-11-04
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT01118845 2013-07-04
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
SymBio Pharmaceuticals
Phase 2 Completed
NCT00992134 2012-09-26
Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma
St. Bortolo Hospital
Phase 2 Completed
NCT00612183 2010-07-22
Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
SymBio Pharmaceuticals
Phase 2 Completed